DOCSLIB.ORG

Record Type Mesh UI 2019 Heading Term Type Term Record Type Mesh UI 2020 Heading New MH SCR C002839 Sennosides Prefterm Sennosid

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Record Type Mesh UI 2019 Heading Term Type Term Record Type Mesh UI 2020 Heading New MH SCR C002839 Sennosides Prefterm Sennosid Record Type MeSH UI 2019 Heading Term Type Term Record Type MeSH UI 2020 Heading New MH SCR C002839 sennosides PrefTerm sennosides Descriptor D000081226 Sennosides Y SCR C002839 sennosides EntryTerm sennoside A&B Descriptor D000081226 Sennosides SCR C002839 sennosides EntryTerm sennoside A, calcium salt Descriptor D000081226 Sennosides SCR C002839 sennosides EntryTerm sennoside A calcium and sennoside B calciu Descriptor D000081226 Sennosides SCR C002839 sennosides EntryTerm sennoside A+B calcium Descriptor D000081226 Sennosides SCR C002839 sennosides EntryTerm sennoside A, calcium salt (1:1) Descriptor D000081226 Sennosides SCR C002839 sennosides EntryTerm Pursennid Descriptor D000081226 Sennosides SCR C002839 sennosides EntryTerm Senokot Descriptor D000081226 Sennosides SCR C002839 sennosides EntryTerm sennosides A and B acids Descriptor D000081226 Sennosides SCR C002839 sennosides EntryTerm sennoside A calcium Descriptor D000081226 Sennosides SCR C002839 sennosides EntryTerm sennoside A&B, calcium salt Descriptor D000081226 Sennosides SCR C002839 sennosides EntryTerm sennoside B, calcium salt Descriptor D000081226 Sennosides SCR C002839 sennosides EntryTerm sennoside Descriptor D000081226 Sennosides SCR C002839 sennosides EntryTerm sennoside b calcium Descriptor D000081226 Sennosides SCR C002839 sennosides EntryTerm sennosides A and B Descriptor D000081226 Sennosides SCR C019551 RNA, circular PrefTerm RNA, circular Descriptor D000079962 RNA, Circular Y SCR C019551 RNA, circular EntryTerm closed circular RNA Descriptor D000079962 RNA, Circular SCR C020138 fatty acid elongases PrefTerm fatty acid elongases Descriptor D000081031 Fatty Acid Elongases Y SCR C020138 fatty acid elongases EntryTerm fatty acid elongation enzyme Descriptor D000081031 Fatty Acid Elongases SCR C022507 pyruvate dehydrogenase (acetyl-transferrinPrefTerm pyruvate dehydrogenase (acetyl-transferring) Descriptor D000081382 Pyruvate Dehydrogenase (Acetyl-Transferring) Y SCR C022507 pyruvate dehydrogenase (acetyl-transferrinEntryTerm pyruvate dehydrogenase kinase Descriptor D000081382 Pyruvate Dehydrogenase (Acetyl-Transferring) SCR C022507 pyruvate dehydrogenase (acetyl-transferrinEntryTerm PDH kinase Descriptor D000081382 Pyruvate Dehydrogenase (Acetyl-Transferring) SCR C025536 Allergoid PrefTerm Allergoid Descriptor D000080384 Allergoids SCR C025536 Allergoid EntryTerm HMW-GOID Descriptor D000080384 Allergoids SCR C025536 Allergoid EntryTerm formalized allergoid Descriptor D000080384 Allergoids SCR C031964 ribosomal protein L10 PrefTerm ribosomal protein L10 Descriptor D000080882 Ribosomal Protein L10 Y SCR C031964 ribosomal protein L10 EntryTerm tumor suppressor QM Descriptor D000080882 Ribosomal Protein L10 SCR C031964 ribosomal protein L10 EntryTerm QM tumor suppressor protein Descriptor D000080882 Ribosomal Protein L10 SCR C031964 ribosomal protein L10 EntryTerm 60S ribosomal protein L10 Descriptor D000080882 Ribosomal Protein L10 SCR C031964 ribosomal protein L10 EntryTerm L10 ribosomal protein Descriptor D000080882 Ribosomal Protein L10 SCR C040231 heme-binding protein PrefTerm heme-binding protein Descriptor D000081062 Heme-Binding Proteins SCR C050639 pyruvate transport protein PrefTerm pyruvate transport protein Descriptor D027501 Monocarboxylic Acid Transporters SCR C050639 pyruvate transport protein EntryTerm pyruvate carrier Descriptor D027501 Monocarboxylic Acid Transporters SCR C050639 pyruvate transport protein EntryTerm pyr translocator Descriptor D027501 Monocarboxylic Acid Transporters SCR C050639 pyruvate transport protein EntryTerm pyruvate transporter Descriptor D027501 Monocarboxylic Acid Transporters SCR C061471 DNA topoisomerase III PrefTerm DNA topoisomerase III Descriptor D004264 DNA Topoisomerases, Type I SCR C061471 DNA topoisomerase III EntryTerm TOPO IIIalpha Descriptor D004264 DNA Topoisomerases, Type I SCR C061471 DNA topoisomerase III EntryTerm topo III Descriptor D004264 DNA Topoisomerases, Type I SCR C061471 DNA topoisomerase III EntryTerm topoisomerase III beta Descriptor D004264 DNA Topoisomerases, Type I SCR C061471 DNA topoisomerase III EntryTerm DNA topoisomerase III beta Descriptor D004264 DNA Topoisomerases, Type I SCR C061471 DNA topoisomerase III EntryTerm TOP3 topoisomerase Descriptor D004264 DNA Topoisomerases, Type I SCR C061471 DNA topoisomerase III EntryTerm topoisomerase IIIbeta Descriptor D004264 DNA Topoisomerases, Type I SCR C061471 DNA topoisomerase III EntryTerm DNA topoisomerase III alpha Descriptor D004264 DNA Topoisomerases, Type I SCR C061471 DNA topoisomerase III EntryTerm topoisomerase IIIalpha Descriptor D004264 DNA Topoisomerases, Type I SCR C061471 DNA topoisomerase III EntryTerm TOP3alpha Descriptor D004264 DNA Topoisomerases, Type I SCR C061471 DNA topoisomerase III EntryTerm topoisomerase III Descriptor D004264 DNA Topoisomerases, Type I SCR C063503 proto-oncogene protein bcl-3 PrefTerm proto-oncogene protein bcl-3 Descriptor D000081242 B-Cell Lymphoma 3 Protein SCR C063503 proto-oncogene protein bcl-3 EntryTerm protein c-bcl-3 Descriptor D000081242 B-Cell Lymphoma 3 Protein SCR C063503 proto-oncogene protein bcl-3 EntryTerm proto-oncogene proteins c-bcl-3 Descriptor D000081242 B-Cell Lymphoma 3 Protein SCR C063503 proto-oncogene protein bcl-3 EntryTerm c-bcl-3 protein Descriptor D000081242 B-Cell Lymphoma 3 Protein SCR C064564 sialyl Le(a) ganglioside EntryTerm sialyl Le(a) Descriptor D018395 CA-19-9 Antigen SCR C066397 phospholipid-hydroperoxide glutathione pePrefTerm phospholipid-hydroperoxide glutathione peroxDescriptor D000080662 Phospholipid Hydroperoxide Glutathione Peroxi SCR C066397 phospholipid-hydroperoxide glutathione peEntryTerm PHGPx enzyme Descriptor D000080662 Phospholipid Hydroperoxide Glutathione Peroxi SCR C066397 phospholipid-hydroperoxide glutathione peEntryTerm PH-GPeroxidase Descriptor D000080662 Phospholipid Hydroperoxide Glutathione Peroxi SCR C066397 phospholipid-hydroperoxide glutathione peEntryTerm glutathione peroxidase 4 Descriptor D000080662 Phospholipid Hydroperoxide Glutathione Peroxi SCR C066397 phospholipid-hydroperoxide glutathione peEntryTerm selenium-dependent glutathione peroxidase tDescriptor D000080662 Phospholipid Hydroperoxide Glutathione Peroxi SCR C067134 8-oxo-7-hydrodeoxyguanosine PrefTerm 8-oxo-7-hydrodeoxyguanosine Descriptor D000080242 8-Hydroxy-2'-Deoxyguanosine SCR C067134 8-oxo-7-hydrodeoxyguanosine EntryTerm 7,8-dihydro-8-oxo-2'-deoxyguanosine Descriptor D000080242 8-Hydroxy-2'-Deoxyguanosine SCR C067134 8-oxo-7-hydrodeoxyguanosine EntryTerm 8-hydroxy-2'-deoxyguanosine Descriptor D000080242 8-Hydroxy-2'-Deoxyguanosine Y SCR C067134 8-oxo-7-hydrodeoxyguanosine EntryTerm 8-oxo-7,8-dihydro-2'-deoxyguanosine Descriptor D000080242 8-Hydroxy-2'-Deoxyguanosine SCR C067134 8-oxo-7-hydrodeoxyguanosine EntryTerm 8-oxodG Descriptor D000080242 8-Hydroxy-2'-Deoxyguanosine SCR C067134 8-oxo-7-hydrodeoxyguanosine EntryTerm 2'-deoxy-8-oxo-7,8-dihydroguanosine Descriptor D000080242 8-Hydroxy-2'-Deoxyguanosine SCR C067134 8-oxo-7-hydrodeoxyguanosine EntryTerm 2'-deoxy-8-hydroxyguanosine Descriptor D000080242 8-Hydroxy-2'-Deoxyguanosine SCR C067134 8-oxo-7-hydrodeoxyguanosine EntryTerm 8-oxo-2'-deoxyguanosine Descriptor D000080242 8-Hydroxy-2'-Deoxyguanosine SCR C067134 8-oxo-7-hydrodeoxyguanosine EntryTerm 8-oxo-7,8-dihydrodeoxyguanosine Descriptor D000080242 8-Hydroxy-2'-Deoxyguanosine SCR C067134 8-oxo-7-hydrodeoxyguanosine EntryTerm 8-oxo-dGuo Descriptor D000080242 8-Hydroxy-2'-Deoxyguanosine SCR C067134 8-oxo-7-hydrodeoxyguanosine EntryTerm 7-hydro-8-oxodeoxyguanosine Descriptor D000080242 8-Hydroxy-2'-Deoxyguanosine SCR C067134 8-oxo-7-hydrodeoxyguanosine EntryTerm 8-hydroxydeoxyguanosine Descriptor D000080242 8-Hydroxy-2'-Deoxyguanosine SCR C067134 8-oxo-7-hydrodeoxyguanosine EntryTerm 8-oxodGuo Descriptor D000080242 8-Hydroxy-2'-Deoxyguanosine SCR C067134 8-oxo-7-hydrodeoxyguanosine EntryTerm 2'-deoxy-7,8-dihydro-8-oxoguanosine Descriptor D000080242 8-Hydroxy-2'-Deoxyguanosine SCR C067134 8-oxo-7-hydrodeoxyguanosine EntryTerm 2'-deoxy-8-oxoguanosine Descriptor D000080242 8-Hydroxy-2'-Deoxyguanosine SCR C067134 8-oxo-7-hydrodeoxyguanosine EntryTerm 8-OH-dG Descriptor D000080242 8-Hydroxy-2'-Deoxyguanosine SCR C067134 8-oxo-7-hydrodeoxyguanosine EntryTerm 8-oxo-dG Descriptor D000080242 8-Hydroxy-2'-Deoxyguanosine SCR C073097 CSK tyrosine-protein kinase PrefTerm CSK tyrosine-protein kinase Descriptor D000081247 CSK Tyrosine-Protein Kinase Y SCR C073097 CSK tyrosine-protein kinase EntryTerm c-src tyrosine kinase Descriptor D000081247 CSK Tyrosine-Protein Kinase SCR C073097 CSK tyrosine-protein kinase EntryTerm carboxy-terminal Src kinase Descriptor D000081247 CSK Tyrosine-Protein Kinase SCR C073097 CSK tyrosine-protein kinase EntryTerm protein-tyrosine kinase c-src Descriptor D000081247 CSK Tyrosine-Protein Kinase SCR C073097 CSK tyrosine-protein kinase EntryTerm tyrosine protein kinase p50csk Descriptor D000081247 CSK Tyrosine-Protein Kinase SCR C073097 CSK tyrosine-protein kinase EntryTerm p50(csk) Descriptor D000081247 CSK Tyrosine-Protein Kinase SCR C073097 CSK tyrosine-protein kinase EntryTerm C-terminal Src kinase Descriptor D000081247 CSK Tyrosine-Protein Kinase SCR C073097 CSK tyrosine-protein kinase EntryTerm CSK-src Descriptor D000081247 CSK Tyrosine-Protein Kinase SCR C073097 CSK tyrosine-protein kinase EntryTerm tyrosine-protein kinase CSK Descriptor D000081247 CSK Tyrosine-Protein Kinase SCR C073097 CSK tyrosine-protein kinase EntryTerm protein tyrosine kinase p50(csk) Descriptor D000081247 CSK Tyrosine-Protein Kinase SCR C073097 CSK
Load more

Recommended publications
  • Supplement 1 Overview of Dystonia Genes
    Supplement 1 Overview of genes that may cause dystonia in children and adolescents Gene (OMIM) Disease name/phenotype Mode of inheritance 1: (Formerly called) Primary dystonias (DYTs): TOR1A (605204) DYT1: Early-onset generalized AD primary torsion dystonia (PTD) TUBB4A (602662) DYT4: Whispering dystonia AD GCH1 (600225) DYT5: GTP-cyclohydrolase 1 AD deficiency THAP1 (609520) DYT6: Adolescent onset torsion AD dystonia, mixed type PNKD/MR1 (609023) DYT8: Paroxysmal non- AD kinesigenic dyskinesia SLC2A1 (138140) DYT9/18: Paroxysmal choreoathetosis with episodic AD ataxia and spasticity/GLUT1 deficiency syndrome-1 PRRT2 (614386) DYT10: Paroxysmal kinesigenic AD dyskinesia SGCE (604149) DYT11: Myoclonus-dystonia AD ATP1A3 (182350) DYT12: Rapid-onset dystonia AD parkinsonism PRKRA (603424) DYT16: Young-onset dystonia AR parkinsonism ANO3 (610110) DYT24: Primary focal dystonia AD GNAL (139312) DYT25: Primary torsion dystonia AD 2: Inborn errors of metabolism: GCDH (608801) Glutaric aciduria type 1 AR PCCA (232000) Propionic aciduria AR PCCB (232050) Propionic aciduria AR MUT (609058) Methylmalonic aciduria AR MMAA (607481) Cobalamin A deficiency AR MMAB (607568) Cobalamin B deficiency AR MMACHC (609831) Cobalamin C deficiency AR C2orf25 (611935) Cobalamin D deficiency AR MTRR (602568) Cobalamin E deficiency AR LMBRD1 (612625) Cobalamin F deficiency AR MTR (156570) Cobalamin G deficiency AR CBS (613381) Homocysteinuria AR PCBD (126090) Hyperphelaninemia variant D AR TH (191290) Tyrosine hydroxylase deficiency AR SPR (182125) Sepiaterine reductase
    [Show full text]
  • 1 Silencing Branched-Chain Ketoacid Dehydrogenase Or
    bioRxiv preprint doi: https://doi.org/10.1101/2020.02.21.960153; this version posted February 22, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Silencing branched-chain ketoacid dehydrogenase or treatment with branched-chain ketoacids ex vivo inhibits muscle insulin signaling Running title: BCKAs impair insulin signaling Dipsikha Biswas1, PhD, Khoi T. Dao1, BSc, Angella Mercer1, BSc, Andrew Cowie1 , BSc, Luke Duffley1, BSc, Yassine El Hiani2, PhD, Petra C. Kienesberger1, PhD, Thomas Pulinilkunnil1†, PhD 1Department of Biochemistry and Molecular Biology, Dalhousie Medicine New Brunswick, Saint John, New Brunswick, Canada, 2Department of Physiology and Biophysics, Dalhousie University, Halifax, Nova Scotia, Canada. †Correspondence to Thomas Pulinilkunnil, PhD Department of Biochemistry and Molecular Biology, Faculty of Medicine, Dalhousie University Dalhousie Medicine New Brunswick, 100 Tucker Park Road, Saint John E2L4L5, New Brunswick, Canada. Telephone: (506) 636-6973; Fax: (506) 636-6001; email: [email protected]. 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.02.21.960153; this version posted February 22, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International
    [Show full text]
  • Transglutaminase-Catalyzed Inactivation Of
    Proc. Natl. Acad. Sci. USA Vol. 94, pp. 12604–12609, November 1997 Medical Sciences Transglutaminase-catalyzed inactivation of glyceraldehyde 3-phosphate dehydrogenase and a-ketoglutarate dehydrogenase complex by polyglutamine domains of pathological length ARTHUR J. L. COOPER*†‡§, K.-F. REX SHEU†‡,JAMES R. BURKE¶i,OSAMU ONODERA¶i, WARREN J. STRITTMATTER¶i,**, ALLEN D. ROSES¶i,**, AND JOHN P. BLASS†‡,†† Departments of *Biochemistry, †Neurology and Neuroscience, and ††Medicine, Cornell University Medical College, New York, NY 10021; ‡Burke Medical Research Institute, Cornell University Medical College, White Plains, NY 10605; and Departments of ¶Medicine, **Neurobiology, and iDeane Laboratory, Duke University Medical Center, Durham, NC 27710 Edited by Louis Sokoloff, National Institutes of Health, Bethesda, MD, and approved August 28, 1997 (received for review April 24, 1997) ABSTRACT Several adult-onset neurodegenerative dis- Q12-containing peptide (16). In the work of Kahlem et al. (16) the eases are caused by genes with expanded CAG triplet repeats largest Qn domain studied was Q18. We found that both a within their coding regions and extended polyglutamine (Qn) nonpathological-length Qn domain (n 5 10) and a longer, patho- domains within the expressed proteins. Generally, in clinically logical-length Qn domain (n 5 62) are excellent substrates of affected individuals n > 40. Glyceraldehyde 3-phosphate dehy- tTGase (17, 18). drogenase binds tightly to four Qn disease proteins, but the Burke et al. (1) showed that huntingtin, huntingtin-derived significance of this interaction is unknown. We now report that fragments, and the dentatorubralpallidoluysian atrophy protein purified glyceraldehyde 3-phosphate dehydrogenase is inacti- bind selectively to glyceraldehyde 3-phosphate dehydrogenase vated by tissue transglutaminase in the presence of glutathione (GAPDH) in human brain homogenates and to immobilized S-transferase constructs containing a Qn domain of pathological rabbit muscle GAPDH.
    [Show full text]
  • 1 Silencing Branched-Chain Ketoacid Dehydrogenase Or
    bioRxiv preprint doi: https://doi.org/10.1101/2020.02.21.960153; this version posted February 22, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Silencing branched-chain ketoacid dehydrogenase or treatment with branched-chain ketoacids ex vivo inhibits muscle insulin signaling Running title: BCKAs impair insulin signaling Dipsikha Biswas1, PhD, Khoi T. Dao1, BSc, Angella Mercer1, BSc, Andrew Cowie1 , BSc, Luke Duffley1, BSc, Yassine El Hiani2, PhD, Petra C. Kienesberger1, PhD, Thomas Pulinilkunnil1†, PhD 1Department of Biochemistry and Molecular Biology, Dalhousie Medicine New Brunswick, Saint John, New Brunswick, Canada, 2Department of Physiology and Biophysics, Dalhousie University, Halifax, Nova Scotia, Canada. †Correspondence to Thomas Pulinilkunnil, PhD Department of Biochemistry and Molecular Biology, Faculty of Medicine, Dalhousie University Dalhousie Medicine New Brunswick, 100 Tucker Park Road, Saint John E2L4L5, New Brunswick, Canada. Telephone: (506) 636-6973; Fax: (506) 636-6001; email: [email protected]. 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.02.21.960153; this version posted February 22, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International
    [Show full text]
  • Aerobic Glycolysis Fuels Platelet Activation: Small-Molecule Modulators of Platelet Metabolism As Anti-Thrombotic Agents
    ARTICLE Platelet Biology & its Disorders Aerobic glycolysis fuels platelet activation: Ferrata Storti Foundation small-molecule modulators of platelet metabolism as anti-thrombotic agents Paresh P. Kulkarni,1† Arundhati Tiwari,1† Nitesh Singh,1 Deepa Gautam,1 Vijay K. Sonkar,1 Vikas Agarwal2 and Debabrata Dash1 1Department of Biochemistry, Institute of Medical Sciences and 2Department of Cardiology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Haematologica 2019 Pradesh, India Volume 104(4):806-818 † PPK and AT contributed equally to this work. ABSTRACT latelets are critical to arterial thrombosis, which underlies myocardial infarction and stroke. Activated platelets, regardless of the nature of Ptheir stimulus, initiate energy-intensive processesthat sustain throm- bus, while adapting to potential adversities of hypoxia and nutrient depri- vation within the densely packed thrombotic milieu. We report here that stimulated platelets switch their energy metabolism to robicae glycolysis by modulating enzymes at key checkpoints in glucose metabolism. We found that aerobic glycolysis, in turn, accelerates flux through the pentose phos- phate pathway and supports platelet activation. Hence, reversing metabolic adaptations of platelets could be an effective alternative to conventional anti-platelet approaches, which are crippled by remarkable redundancy in platelet agonists and ensuing signaling pathways. In support of this hypoth- esis, small-molecule modulators of pyruvate dehydrogenase, pyruvate kinase M2 and glucose-6-phosphate dehydrogenase, all of which impede aerobic glycolysis and/or the pentose phosphate pathway, restrained the Correspondence: agonist-induced platelet responsesex vivo. These drugs, which include the DEBABRATA DASH anti-neoplastic candidate, dichloroacetate, and the Food and Drug [email protected] Administration-approved dehydroepiandrosterone, profoundly impaired thrombosis in mice, thereby exhibiting potential as anti-thrombotic agents.
    [Show full text]
  • Emerging Roles of P53 Family Members in Glucose Metabolism
    International Journal of Molecular Sciences Review Emerging Roles of p53 Family Members in Glucose Metabolism Yoko Itahana and Koji Itahana * Cancer and Stem Cell Biology Program, Duke-NUS Medical School, 8 College Road, Singapore 169857, Singapore; [email protected] * Correspondence: [email protected]; Tel.: +65-6516-2554; Fax: +65-6221-2402 Received: 19 January 2018; Accepted: 22 February 2018; Published: 8 March 2018 Abstract: Glucose is the key source for most organisms to provide energy, as well as the key source for metabolites to generate building blocks in cells. The deregulation of glucose homeostasis occurs in various diseases, including the enhanced aerobic glycolysis that is observed in cancers, and insulin resistance in diabetes. Although p53 is thought to suppress tumorigenesis primarily by inducing cell cycle arrest, apoptosis, and senescence in response to stress, the non-canonical functions of p53 in cellular energy homeostasis and metabolism are also emerging as critical factors for tumor suppression. Increasing evidence suggests that p53 plays a significant role in regulating glucose homeostasis. Furthermore, the p53 family members p63 and p73, as well as gain-of-function p53 mutants, are also involved in glucose metabolism. Indeed, how this protein family regulates cellular energy levels is complicated and difficult to disentangle. This review discusses the roles of the p53 family in multiple metabolic processes, such as glycolysis, gluconeogenesis, aerobic respiration, and autophagy. We also discuss how the dysregulation of the p53 family in these processes leads to diseases such as cancer and diabetes. Elucidating the complexities of the p53 family members in glucose homeostasis will improve our understanding of these diseases.
    [Show full text]
  • Glycolysis Citric Acid Cycle Oxidative Phosphorylation Calvin Cycle Light
    Stage 3: RuBP regeneration Glycolysis Ribulose 5- Light-Dependent Reaction (Cytosol) phosphate 3 ATP + C6H12O6 + 2 NAD + 2 ADP + 2 Pi 3 ADP + 3 Pi + + 1 GA3P 6 NADP + H Pi NADPH + ADP + Pi ATP 2 C3H4O3 + 2 NADH + 2 H + 2 ATP + 2 H2O 3 CO2 Stage 1: ATP investment ½ glucose + + Glucose 2 H2O 4H + O2 2H Ferredoxin ATP Glyceraldehyde 3- Ribulose 1,5- Light Light Fx iron-sulfur Sakai-Kawada, F Hexokinase phosphate bisphosphate - 4e + center 2016 ADP Calvin Cycle 2H Stroma Mn-Ca cluster + 6 NADP + Light-Independent Reaction Phylloquinone Glucose 6-phosphate + 6 H + 6 Pi Thylakoid Tyr (Stroma) z Fe-S Cyt f Stage 1: carbon membrane Phosphoglucose 6 NADPH P680 P680* PQH fixation 2 Plastocyanin P700 P700* D-(+)-Glucose isomerase Cyt b6 1,3- Pheophytin PQA PQB Fructose 6-phosphate Bisphosphoglycerate ATP Lumen Phosphofructokinase-1 3-Phosphoglycerate ADP Photosystem II P680 2H+ Photosystem I P700 Stage 2: 3-PGA Photosynthesis Fructose 1,6-bisphosphate reduction 2H+ 6 ADP 6 ATP 6 CO2 + 6 H2O C6H12O6 + 6 O2 H+ + 6 Pi Cytochrome b6f Aldolase Plastoquinol-plastocyanin ATP synthase NADH reductase Triose phosphate + + + CO2 + H NAD + CoA-SH isomerase α-Ketoglutarate + Stage 2: 6-carbonTwo 3- NAD+ NADH + H + CO2 Glyceraldehyde 3-phosphate Dihydroxyacetone phosphate carbons Isocitrate α-Ketoglutarate dehydogenase dehydrogenase Glyceraldehyde + Pi + NAD Isocitrate complex 3-phosphate Succinyl CoA Oxidative Phosphorylation dehydrogenase NADH + H+ Electron Transport Chain GDP + Pi 1,3-Bisphosphoglycerate H+ Succinyl CoA GTP + CoA-SH Aconitase synthetase
    [Show full text]
  • Lipoyl Moieties in the Pyruvate and A-Ketoglutarate Dehydrogenase
    Vol. 74, No. 10, pp 42&S-4227, October 1977 Biochemistry Acyl group and electron pair relay system: A network of interacting lipoyl moieties in the pyruvate and a-ketoglutarate dehydrogenase complexes from Escherichia coli (multienzyme complexes/thiol-disulfide interchange/crosslinking of subunits) JIMMY H. COLLINS AND LESTER J. REED Clayton Foundation Biochemical Institute and Department of Chemistry, The University of Texas at Austin, Austin, Texas 78712 Contributed by Lester J. Reed, August 18, 1977 ABSTRACT The dihydrolipoyl transacetylase component complex by [2-'4C]pyruvate (6) and of the pyruvate-dependent of the Escherichia coli pyruvate dehydrogenase complex [pyr- reaction of N-ethyl[2,3-14C]maleimide with the complex (7) uvate:lipoate oxidoreductase (decarboxylating and acceptor- indicate the presence of two functionally active lipoyl acetylating), EC 1.2.4.11 bears two sites on each of its 24poly- moieties peptide chains that undergo reductive acetylation by on each transacetylase chain. 2-4C pyruvate and thiamin pyrophosphate, acetylation by In this communication, we confirm and extend this latter [lMClacetyl-CoA in the presence of DPNH, and reaction with finding, and we present evidence indicating that the trans- N-ethyl[2,3-14Clmaleimide in the presence of pyruvate and succinylase component of the a-ketoglutarate dehydrogenase thiamin pyrophosphate. The data strongly ir tat these sites complex bears one functionally active lipoyl moiety per chain are covalent y bound lipoyl moieties. The results of similar ex- and that the 48 lipoyl moieties in periments with the E. coli a-ketoglutarate dehydrogenase the transacetylase and the 24 complex [2-oxoglutaratelipoate oxidoreductase (decarboxylating lipoyl moieties in the transsuccinylase comprise a network that and acceptor-succinylating), EC 1±2.4.2] indicate that its dihy- functions as an acyl group and electron pair relay system drolipoyl transsuccinylase component bears only one lipoyl through thiol-disulfide and acyl-transfer reactions among all moiety on each of its 24 chains.
    [Show full text]
  • Dynamic Control Over Feedback Regulation Identifies Pyruvate-Ferredoxin Oxidoreductase As a Central Metabolic Enzyme in Stationary Phase E
    bioRxiv preprint doi: https://doi.org/10.1101/2020.07.26.219949; this version posted August 10, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Dynamic control over feedback regulation identifies pyruvate-ferredoxin oxidoreductase as a central metabolic enzyme in stationary phase E. coli. ​ 1,* 2,* 2 2 2,3, + Shuai Li ,​ Zhixia Ye ,​ Juliana Lebeau ,​ Eirik A. Moreb ,and​ Michael D. Lynch 1 ​ ​ ​ ​ ​ Department​ of Chemistry, Duke University 2 Department​ of Biomedical Engineering, Duke University *Authors contributed equally to this work. 3 To​ whom all correspondence should be addressed. [email protected] Abstract: We demonstrate the use of two-stage dynamic metabolic control to manipulate ​ feedback regulation in central metabolism and improve stationary phase biosynthesis in engineered E. coli. Specifically, we report the impact of dynamic control over two enzymes: ​ citrate synthase, and glucose-6-phosphate dehydrogenase, on stationary phase fluxes. Firstly, ​ ​ ​ ​ reduced citrate synthase levels lead to a reduction in 휶-ketoglutarate, which is an inhibitor of sugar transport, resulting in increased stationary phase glucose uptake and glycolytic fluxes. Reduced glucose-6-phosphate dehydrogenase activity activates the SoxRS regulon and expression of pyruvate-ferredoxin oxidoreductase, which is in turn responsible for large increases in acetyl-CoA production. The combined reduction in citrate synthase and glucose-6-phosphate dehydrogenase, leads to greatly enhanced stationary phase metabolism and ​ the improved production of citramalic acid enabling titers of 126±7g/L. These results identify pyruvate oxidation via the pyruvate-ferredoxin oxidoreductase as a “central” metabolic pathway in stationary phase E.
    [Show full text]
  • The Spectrum of Pyruvate Dehydrogenase Complex Deficiency
    Molecular Genetics and Metabolism 105 (2012) 34–43 Contents lists available at SciVerse ScienceDirect Molecular Genetics and Metabolism journal homepage: www.elsevier.com/locate/ymgme Minireview The spectrum of pyruvate dehydrogenase complex deficiency: Clinical, biochemical and genetic features in 371 patients Kavi P. Patel a, Thomas W. O'Brien b, Sankarasubramon H. Subramony c, Jonathan Shuster d, Peter W. Stacpoole a,b,⁎ a Departments of Medicine (Division of Endocrinology and Metabolism), College of Medicine, University of Florida, Gainesville, FL 32611, USA b Biochemistry and Molecular Biology, College of Medicine, University of Florida, Gainesville, FL 32611, USA c Neurology, College of Medicine, University of Florida, Gainesville, FL 32611, USA d Epidemiology and Health Policy Research, College of Medicine, University of Florida, Gainesville, FL 32611, USA article info abstract Article history: Context: Pyruvate dehydrogenase complex (PDC) deficiency is a genetic mitochondrial disorder commonly Received 2 September 2011 associated with lactic acidosis, progressive neurological and neuromuscular degeneration and, usually, Received in revised form 27 September 2011 death during childhood. There has been no recent comprehensive analysis of the natural history and clinical Accepted 27 September 2011 course of this disease. Available online 7 October 2011 Objective: We reviewed 371 cases of PDC deficiency, published between 1970 and 2010, that involved defects in subunits E1α and E1β and components E1, E2, E3 and the E3 binding protein of the complex. Keywords: Data sources and extraction: English language peer-reviewed publications were identified, primarily by using Congenital lactic acidosis Dichloroacetate PubMed and Google Scholar search engines. Neuroimaging Results: Neurodevelopmental delay and hypotonia were the commonest clinical signs of PDC deficiency.
    [Show full text]
  • Paroxysmal Spasticity of Lower Extremities As the Initial Symptom in Two Siblings with Maple Syrup Urine Disease
    4872 MOLECULAR MEDICINE REPORTS 19: 4872-4880, 2019 Paroxysmal spasticity of lower extremities as the initial symptom in two siblings with maple syrup urine disease YI-DAN LIU1*, XU CHU2*, RUI-HUA LIU3, YING SUN1, QING-XIA KONG2 and QIU-BO LI3 1Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250012; Departments of 2Neurology and 3Pediatrics, Affiliated Hospital of Jining Medical University, Jining, Shandong 272000, P.R. China Received July 31, 2018; Accepted April 1, 2019 DOI: 10.3892/mmr.2019.10133 Abstract. Maple syrup urine disease (MSUD) is a rare heterozygous mutations in the BCKDHB gene found in the autosomal recessive metabolic disorder caused by muta- Chinese family may be responsible for the phenotype of the tions in genes that encode subunits of the branched-chain two siblings with MSUD. α-ketoacid dehydrogenase (BCKD) complex. Impairment of the BCKD complex results in an abnormal accumulation Introduction of branched-chain amino acids and their corresponding branched‑chain keto acids in the blood and cerebrospinal fluid, In the wide array of inherited metabolic disorders, maple which are neurovirulent and may become life-threatening. An syrup urine disease (MSUD; Online Mendelian Inheritance 11-day-old boy was admitted to the hospital with paroxysmal in Man no. 248600; https://www.omim.org/entry/248600) has spasticity of lower extremities. Of note, his 10-year-old sister attracted increasing attention due to the potential neurological presented similar symptoms during the neonatal period, and damage caused by this disorder (1). MSUD was first reported her condition was diagnosed as MSUD when she was 1.5 years by Menkes et al (2) in 1954.
    [Show full text]
  • 1,2,3,5,6,8,10,11,16,20,21 Citric Acid Cycle Reactions
    Overview of the citric acid cycle, AKA the krebs cycle AKA tricarboxylic acid AKA TCA cycle Suggested problems from the end of chapter 19: 1,2,3,5,6,8,10,11,16,20,21 Glycogen is broken down into glucose. The reactions of glycolysis result in pyruvate, which is then fed into the citric acid cycle in the form of acetyl CoA. The products of the citric acid cycles are 2 CO2, 3 NADH, 1 FADH2, and 1 ATP or GTP. After pyruvate is generated, it is transported into the mitochondrion, an organelle that contains the citric acid cycle enzymes and the oxidative phosphorylation enzymes. In E. coli, where there are neither mitochondria nor other organelles, these enzymes also seem to be concentrated in certain regions in the cell. Citric acid cycle reactions Overall, there are 8 reactions that result in oxidation of the metabolic fuel. This results in reduction of NAD+ and FAD. NADH and FADH2 will transfer their electrons to oxygen during oxidative phosphorylation. •In 1936 Carl Martius and Franz Knoop showed that citrate can be formed non-enzymaticly from Oxaloacetate and pyruvate. •In 1937 Hans Krebs used this information for biochemical experiments that resulted in his suggestion that citrate is processed in an ongoing circle, into which pyruvate is “fed.” •In 1951 it was shown that it was acetyl Coenzyme-A that condenses with oxaloacetate to form citrate. 1 The pre-citric acid reaction- pyruvate dehydrogenase Pyruvate dehydrogenase is a multi-subunit complex, containing three enzymes that associate non-covalently and catalyze 5 reaction. The enzymes are: (E1) pyruvate dehydrogenase (E2) dihydrolipoyl transacetylase (E3) dihydrolipoyl dehydrogenase What are the advantages for arranging enzymes in complexes? E.
    [Show full text]